FREMONT, Calif., Aug. 2, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a late-stage clinical company focused on enhancing the treatment of patients with cardiorenal and gastrointestinal (GI) diseases, today announced that management will host a conference call in conjunction with its second quarter 2017 financial results and present at the 2017 Wedbush PacGrow Healthcare Conference. Details of both events are as follows:
- Second Quarter 2017 Financial Results: Management will host a conference call and webcast on Wednesday, August 9, 2017, at 8:00 a.m. ET to provide a business update and review second quarter 2017 financial results. To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 47784045. The webcast can be accessed under "Events and Presentations" in the investor section of the company's website at www.ardelyx.com.
- Wedbush PacGrow Healthcare Conference Presentation: Management will present a company overview at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16, 2017 at 2:30 p.m. ET in New York City. A live webcast of the presentation can be accessed under "Events and Presentations" in the investor section of the company's website at www.ardelyx.com.
Replays of both webcasts will be available in the investor section of the company's website for 60 days following the call and presentation.
About Ardelyx, Inc.
Ardelyx is focused on enhancing the way patients with cardiorenal and gastrointestinal (GI) diseases are treated by using the gut as the gateway to delivering medicines that matter. The company has established unique cardiorenal and GI business portfolios aimed at bringing new, effective medicines with distinct safety and dosing advantages to underserved patients. Ardelyx's cardiorenal portfolio includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and the Phase 3 development of RDX7675 for the treatment of people with hyperkalemia. The company's GI portfolio includes the Phase 3 development of tenapanor for the treatment of people with irritable bowel syndrome with constipation (IBS-C), and RDX8940, a TGR5 agonist approaching Phase 1 development. For more information, please visit www.ardelyx.com and connect with us on Twitter @Ardelyx.
View original content with multimedia:http://www.prnewswire.com/news-releases/ardelyx-announces-date-of-second-quarter-financial-results-and-presentation-at-wedbush-pacgrow-healthcare-conference-300498033.html